SubHero Banner

Opdivo® (nivolumab), Yervoy® (ipilimumab) – New indication

May 26, 2020 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with Yervoy (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

Download PDF